Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
40S ribosomal protein S30 (FAU) is a human protein encoded by the FAU gene, which produces a fusion protein consisting of an N-terminal ubiquitin-like domain (FUBI) and a C-terminal ribosomal protein S30[1][2][3][4]. In cells, the fusion is cleaved post-translationally, separating FUBI from S30; only S30 becomes part of the mature 40S ribosomal subunit and acts in the cytoplasmic ribosome to facilitate mRNA translation[1][2][4]. FUBI shares moderate structural similarity with ubiquitin but its cellular roles are less defined; however, both intact FAU and its FUBI domain have been implicated in the regulation of apoptosis (programmed cell death) through interactions with proteins such as Bcl-G, and the gene is considered a potential tumor suppressor[2]. Downregulation of FAU may increase resistance to apoptosis and be linked to tumor progression in cancer, suggesting its function as a biomarker for tumor suppression and prognosis[2]. There are currently no well-established therapeutics or drugs known to specifically target FAU directly, and drug mechanism-of-action or safety profiles are not documented for this protein.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 40S ribosomal protein S30 (FAU).